DiaMedica Competitors

Stocks . USA . 
Stock . DiaMedica Therapeutics
DMAC Stock  USD 7.54  0.36  4.56%   
DiaMedica Therapeutics competes with Altimmune, Galectin Therapeutics, EnGene Holdings, Annexon, and Alpha Tau; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing DiaMedica Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of DiaMedica Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out DiaMedica Therapeutics Correlation with its peers.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.

DiaMedica Therapeutics vs Genelux Common Correlation

Very good diversification

The correlation between DiaMedica Therapeutics and GNLX is -0.38 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding DiaMedica Therapeutics and GNLX in the same portfolio, assuming nothing else is changed.

Moving together with DiaMedica Stock

  0.66DSGN Design TherapeuticsPairCorr

Moving against DiaMedica Stock

  0.52EVGN EvogenePairCorr
  0.45KRRO Frequency TherapeuticsPairCorr
  0.4IMRN Immuron Ltd ADRPairCorr
  0.38GNLX Genelux CommonPairCorr
  0.36EDIT Editas MedicinePairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
2.787.5412.30
Details
Intrinsic
Valuation
LowRealHigh
2.717.4712.23
Details
Naive
Forecast
LowNextHigh
2.437.2011.96
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
7.568.419.27
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as DiaMedica Therapeutics. Your research has to be compared to or analyzed against DiaMedica Therapeutics' peers to derive any actionable benefits. When done correctly, DiaMedica Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in DiaMedica Therapeutics.

DiaMedica Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between DiaMedica Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of DiaMedica and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of DiaMedica Therapeutics does not affect the price movement of the other competitor.

High positive correlations

DRTS
+ 0.89
ANNX
DSGN
+ 0.87
ANNX
DBVT
+ 0.82
ANNX
ANNX
+ 0.79
ENGN
DSGN
+ 0.79
ENGN
DBVT
+ 0.79
DRTS
  

High negative correlations

GNLX
- 0.87
ANNX
GNLX
- 0.82
DRTS
GNLX
- 0.81
DSGN
GNLX
- 0.71
ENGN
DRTS
- 0.69
GALT
GNLX
- 0.68
DBVT

Risk-Adjusted Indicators

There is a big difference between DiaMedica Stock performing well and DiaMedica Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze DiaMedica Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ALT  4.05  0.50  0.09  0.60  5.19 
(5.13)
 9.80 
(6.22)
 33.75 
GALT  4.65 (0.78) 0.00  4.47  0.00 
 0.00 
 8.89 
(8.92)
 39.42 
ENGN  4.47  0.56  0.14  0.21  4.29 
(5.59)
 11.36 
(6.92)
 61.40 
IMAB  4.25  0.40  0.07 (0.61) 4.63 
(5.23)
 10.53 
(8.92)
 33.43 
ANNX  4.10  1.25  0.32 (6.28) 3.10 
(5.24)
 11.30 
(6.57)
 35.10 
DRTS  4.08  0.76  0.18  0.23  3.94 
(4.57)
 10.48 
(7.29)
 28.89 
KRRO  5.13 (0.80) 0.00 (0.11) 0.00 
 0.00 
 10.98 
(6.62)
 83.21 
DSGN  3.53  0.73  0.18  3.27  3.63 
(3.96)
 9.28 
(5.98)
 18.90 
DBVT  4.22  0.98  0.21 (0.84) 3.71 
(5.21)
 10.53 
(6.66)
 36.36 
GNLX  3.96 (1.47) 0.00 (24.72) 0.00 
 0.00 
 5.67 
(11.87)
 34.38 

DiaMedica Therapeutics Competitive Analysis

The better you understand DiaMedica Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, DiaMedica Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across DiaMedica Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
DMAC ALT GALT ENGN IMAB ANNX DRTS KRRO DSGN DBVT
 4.56 
 7.54 
DiaMedica
 6.22 
 5.13 
Altimmune
 8.92 
 2.96 
Galectin
 3.81 
 9.59 
EnGene
 0.51 
 3.98 
IMAB
 6.79 
 6.04 
Annexon
 9.74 
 6.86 
Alpha
 5.87 
 11.54 
Frequency
 3.57 
 10.00 
Design
 4.04 
 23.41 
DBV
Market Volatility
(90 Days Market Risk)
Slightly risky
Moderately volatile
Risky
Moderately volatile
Relatively risky
Moderately volatile
Moderately volatile
Moderately volatile
Somewhat reliable
Not too volatile
Market Performance
(90 Days Performance)
Fair
Mild
Weakest
Fair
Weak
Solid
Solid
Weakest
Fair
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Small
Small
Risky
Low
Hazard
Low
Low
Risky
Moderate
Low
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Under Valued
Under Valued
Under Valued
Fairly Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Strong Buy
Not Available
Strong Buy
Strong Buy
Strong Buy
Buy
Buy
Trade Advice
(90 Days Macroaxis Advice)
Hold
Cautious Hold
Strong Sell
Cautious Hold
Not Rated
Strong Sell
Hold
Sell
Hold
Strong Sell
Current Ratio
25.5
14.12
1.79
N/A
7.31
8.95
41.98
N/A
48.96
8.54
Net Asset
46.34 M
139.31 M
17.5 M
221.47 M
212.68 M
350.07 M
86.2 M
226.24 M
252.09 M
65.66 M
EBITDA
(26.64 M)
(94.81 M)
(41.47 M)
(113.8 M)
(373.45 M)
(134.75 M)
(30.3 M)
(88.34 M)
(48.99 M)
(110.99 M)
Current Valuation
370.94 M
500.16 M
304.7 M
507.91 M
313.92 M
789.19 M
591.86 M
75.08 M
388.77 M
1.16 B
Price To Book
8.47
3.69
207.7
3.99
2.42
5.98
8.39
1.24
2.95
23.08
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-17.65
N/A
-12.36
Retained Earnings
(140 M)
(561.39 M)
(401.57 M)
(372.03 M)
(1.29 B)
(710.7 M)
(147.51 M)
(266.59 M)
(227.21 M)
(286.38 M)
Current Asset
5.24 M
13.9 M
26.4 M
N/A
1.51 B
N/A
N/A
N/A
N/A
334.89 M
One Year Return
N/A
-6.49
N/A
4.07
N/A
N/A
N/A
N/A
N/A
N/A
Beta
1.08
0.076
0.99
-0.28
1.46
1.14
1.05
2.44
1.64
-0.19
Number Of Employees
27
59
15
81
32
99
125
87
55
117
Equity Positions Weight
N/A
21.57
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Outstanding
52.08 M
125.23 M
64.47 M
66.98 M
115.27 M
149.06 M
85.26 M
9.42 M
56.96 M
54.29 M
Three Year Return
N/A
-0.57
N/A
3.14
N/A
N/A
N/A
N/A
N/A
N/A
Cash Flow From Operations
(22.08 M)
(79.85 M)
(41.77 M)
(99.24 M)
(52.67 M)
(118.01 M)
(19.78 M)
(60.07 M)
(43.1 M)
(104.47 M)
Total Debt
340 K
1.68 M
106.25 M
31.8 M
3.88 M
28.97 M
12.54 M
44.77 M
2.33 M
7.8 M
Return On Equity
-0.64
-0.53
-37.28
-0.53
-0.18
-0.84
-0.54
-0.63
-0.3
-2.34
Bond Positions Weight
N/A
15.26
N/A
97.03
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.38
-0.31
-0.87
-0.29
-0.1
-0.45
-0.26
-0.29
-0.2
-0.77
Number Of Shares Shorted
4.23 M
26.41 M
4.75 M
1.44 M
3.65 M
18.44 M
527.36 K
1.09 M
2.32 M
1.25 M
Book Value Per Share
0.99
1.94
-1.95
3.22
2.4
1.4
0.91
10.54
3.51
0.39
Current Liabilities
1.05 M
10.49 M
1.36 M
N/A
527.75 M
N/A
N/A
N/A
N/A
16.02 M
Total Asset
46.34 M
139.31 M
17.5 M
221.47 M
212.68 M
350.07 M
86.2 M
226.24 M
252.09 M
65.66 M
Short Ratio
13.5
4.52
6.69
5.46
2.01
6.35
1.54
5.83
4.84
2.12
Target Price
15.5
17.67
11.0
23.91
8.6
14.33
8.25
19.33
14.4
40.17
Debt To Equity
N/A
0.006
N/A
N/A
0.025
0.2
N/A
N/A
0.011
0.016
Shares Owned By Institutions
45.47
40.12
16.36
86.4
21.09
80.03
3.49
93.85
59.33
13.5
Market Capitalization
411.41 M
642.44 M
190.86 M
642.38 M
533.68 M
900.3 M
584.91 M
115.46 M
569.64 M
1.27 B
Price To Earning
-3.52
-1.66
-4.21
N/A
N/A
N/A
N/A
N/A
N/A
-8.25
Price To Earnings To Growth
-0.07
N/A
N/A
N/A
4.35
-0.04
N/A
N/A
N/A
N/A
Price To Sales
N/A
32121.89
N/A
N/A
25.39
N/A
N/A
15.66
22642.01
231.0
Net Income
(24.44 M)
(95.06 M)
(47.05 M)
(117.3 M)
(49.7 M)
(138.2 M)
(31.75 M)
(83.58 M)
(49.59 M)
(113.92 M)
Earnings Per Share
-0.67
-1.0
-0.59
-2.2
-0.51
-1.31
-0.47
-9.09
-1.15
-5.43
Shares Owned By Insiders
26.3
0.64
29.86
0.09
21.39
0.33
32.7
6.15
35.96
N/A
Revenue
N/A
20 K
N/A
N/A
N/A
N/A
N/A
2.27 M
N/A
2.57 M
Year To Date Return
N/A
1.67
N/A
-0.98
N/A
N/A
N/A
N/A
N/A
N/A
Working Capital
39.22 M
126.79 M
(18.16 M)
169.41 M
168.24 M
285.95 M
55.55 M
116.57 M
239.58 M
13.25 M
Cash And Equivalents
38.44 M
184.76 M
15.83 M
N/A
3.92 B
177.59 M
112.04 M
N/A
359.38 M
247.97 M
Cash Per Share
1.45
3.81
0.27
N/A
47.2
3.73
1.63
N/A
6.45
1.32
Gross Profit
N/A
(67.78 M)
N/A
N/A
41.59 M
N/A
N/A
46 K
(57.86 M)
5.5 M
Day Typical Price
7.67
5.25
3.03
9.71
3.98
6.15
7.06
11.77
10.18
23.75
Accumulation Distribution
9474.87
0.0796
0.0991
0.17
0.0394
0.0951
32971.53
13665.8
0.0777
0.0829
Market Facilitation Index
0.0
0.44
0.32
1.81
0.16
0.62
0.0
0.0
0.83
2.07
Daily Balance Of Power
(0.69)
(0.77)
(0.91)
(0.21)
0.125
(0.71)
(1.07)
(0.64)
(0.45)
0.4396
Period Momentum Indicator
(0.36)
(0.34)
(0.29)
(0.38)
0.02
(0.44)
(0.74)
(0.72)
(0.37)
0.91
Rate Of Daily Change
0.95
0.94
0.91
0.96
1.01
0.93
0.9
0.94
0.96
1.04
Day Median Price
7.73
5.31
3.07
9.77
3.98
6.21
7.17
11.89
10.27
23.93
Price Action Indicator
(0.37)
(0.35)
(0.26)
(0.37)
0.01
(0.39)
(0.67)
(0.71)
(0.45)
(0.06)
Coefficient Of Variation
934.17
1127.78
(824.99)
1119.59
1484.95
452.61
614.51
(1,846)
602.84
655.26
Mean Deviation
3.46
4.05
4.65
4.47
4.25
4.1
4.08
5.13
3.53
4.22
Jensen Alpha
0.4238
0.495
(0.78)
0.5611
0.4041
1.25
0.7607
(0.80)
0.7278
0.9813
Total Risk Alpha
0.2775
0.2438
(1.08)
0.3162
0.1105
0.9763
0.6351
(1.13)
0.5259
0.651
Sortino Ratio
0.0974
0.0861
N/A
0.1361
0.071
0.3202
0.1805
N/A
0.1752
0.2119
Downside Variance
22.77
32.45
N/A
21.96
23.87
14.17
22.67
N/A
16.0
18.32
Standard Deviation
4.76
6.04
6.4
7.65
5.82
5.66
5.56
11.12
4.5
6.24
Kurtosis
1.24
4.1
4.99
19.93
2.12
5.32
1.24
39.47
(0.09)
4.62
Potential Upside
7.69
9.8
8.89
11.36
10.53
11.3
10.48
10.98
9.28
10.53
Treynor Ratio
0.2309
0.603
4.47
0.2109
(0.61)
(6.28)
0.2347
(0.11)
3.27
(0.84)
Maximum Drawdown
24.12
33.75
39.42
61.4
33.43
35.1
28.89
83.21
18.9
36.36
Variance
22.67
36.49
40.93
58.47
33.91
32.03
30.88
123.6
20.21
38.92
Market Risk Adjusted Performance
0.2409
0.613
4.48
0.2209
(0.60)
(6.27)
0.2447
(0.10)
3.28
(0.83)
Risk Adjusted Performance
0.0889
0.0754
(0.08)
0.0762
0.0593
0.1748
0.131
(0.03)
0.133
0.1235
Skewness
(0.29)
(0.48)
(1.23)
3.47
0.8503
1.6
0.7818
(5.48)
0.4017
1.59
Semi Deviation
4.47
5.19
N/A
4.29
4.63
3.1
3.94
N/A
3.63
3.71
Information Ratio
0.0976
0.0812
(0.13)
0.0834
0.0596
0.213
0.1546
(0.06)
0.1559
0.1454
Value At Risk
(6.28)
(6.22)
(8.92)
(6.92)
(8.92)
(6.57)
(7.29)
(6.62)
(5.98)
(6.66)
Expected Short fall
(3.80)
(5.13)
N/A
(5.59)
(5.23)
(5.24)
(4.57)
N/A
(3.96)
(5.21)
Downside Deviation
4.77
5.7
N/A
4.69
4.89
3.76
4.76
N/A
4.0
4.28
Semi Variance
19.97
26.92
N/A
18.39
21.48
9.61
15.49
N/A
13.17
13.74

DiaMedica Therapeutics Competition Performance Charts

Five steps to successful analysis of DiaMedica Therapeutics Competition

DiaMedica Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by DiaMedica Therapeutics in relation to its competition. DiaMedica Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of DiaMedica Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact DiaMedica Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to DiaMedica Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your DiaMedica Therapeutics position

In addition to having DiaMedica Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Baby Boomer Prospects Thematic Idea Now

Baby Boomer Prospects
Baby Boomer Prospects Theme
Equities with large market capitalization that account for significant contribution to overall economic growth especially within dividend-paying instruments and stocks from healthcare and financial sectors. The Baby Boomer Prospects theme has 100 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Baby Boomer Prospects Theme or any other thematic opportunities.
View All  Next Launch
When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:
How To Invest In DiaMedica
Details
Is DiaMedica Stock a good investment?
Details
What is DiaMedica Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out DiaMedica Therapeutics Correlation with its peers.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Will Biotechnology sector continue expanding? Could DiaMedica diversify its offerings? Factors like these will boost the valuation of DiaMedica Therapeutics. Projected growth potential of DiaMedica fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DiaMedica Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
It's important to distinguish between DiaMedica Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DiaMedica Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DiaMedica Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY